Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients
Alana F. Ogata, Chi‐An Cheng, Michaël Desjardins, Yasmeen Senussi, Amy C Sherman, Megan Powell, Lewis A. Novack, Salena S Von, Xiaofang Li, Lindsey R. Baden, David R. Walt
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. Eleven of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of immunoglobulin G (IgG) and immunoglobulin A (IgA).
Topics & Concepts
MedicineCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AntibodyImmunologyRespiratory systemVirologyImmunoglobulin GSevere acute respiratory syndrome coronavirusCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndromeAntigenInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies